Truist Securities has maintained its coverage of Arcutis Biotherapeutics (NASDAQ:ARQT) on May 26, 2023, with a Buy recommendation, according to Fintel reports.
The average one-year price target for Arcutis Biotherapeutics, as of May 11, 2023, is 47.15, with a range of 24.24 to $68.25. The average price target represents a potential increase of 461.27% from its latest reported closing price of $8.40.
Arcutis Biotherapeutics is expected to reach an annual revenue of $53MM, an increase of 726.43%. The projected annual non-GAAP EPS is -4.69.
According to Fintel data, there are 354 funds or institutions reporting positions in Arcutis Biotherapeutics. The put/call ratio of ARQT is 0.75, indicating a bullish outlook. Additionally, the projected annual revenue for Arcutis Biotherapeutics is 53MM, an increase of 726.43%.
Leading institutions that hold ARQT shares include Frazier Life Sciences Management, Rubric Capital Management, Polar Capital Holdings, and Bain Capital Life Sciences Investors.
Arcutis Biotherapeutics is a late-stage biopharmaceutical company that focuses on solving persistent treatment challenges in serious diseases of the skin. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies.
This story first appeared on Fintel’s website.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
